SCHEMBL6735264

SCHEMBL6735264

Cc1oc(Cc2ccc(Br)cc2)c(C(=O)c2ccc(S(=O)(=O)c3ccc(C(=O)O)c(O)c3)c(C3CCCC3)c2)c1C

nearest known ligand 0.40

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 3/20 0.40
STAT3 P40763 16/20 0.40
MCL1 Q07820 1/20 0.33
STAT5B P51692 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6736467 0.88 PTPN1 (0.55) PTPN1STAT3
SCHEMBL6740349 0.82 NUDT1 (0.37)
SCHEMBL6736222 0.81 PTPN1 (0.62) PTPN1STAT3MCL1
SCHEMBL7083770 0.79 PTPN1 (0.45) PTPN1STAT3
SCHEMBL6734073 0.77 PTGDR2 (0.39) PTPN1
SCHEMBL6731316 0.77 PTPN1 (0.52) PTPN1STAT3
SCHEMBL6731410 0.75 PTPN1 (0.37) PTPN1MCL1
SCHEMBL6734542 0.73 PTPN1 (0.45) PTPN1STAT3MCL1
SCHEMBL6731859 0.73 PTPN1 (0.48) PTPN1STAT3
SCHEMBL6736759 0.72 PTPN1 (0.51) PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6683107-B2 THERAPY OF METABOLISM DISORDERS WYETH 2004-01-27 US disclosed
US-20030073709-A1 Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia WYETH 2003-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073709-A1 Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia GPR119, INSR, FFAR3 PTPN1 178/4885STAT3 3470/4885MCL1 3680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.